Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2021 - 03 - 15 save search
Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND to Initiate a Phase 1/2 Trial for Knee Cartilage Regeneration
Published: 2021-03-15 (Crawled : 16:00) - biospace.com/
HSTO 4 d | $0.35 67.46% 5.4K
|
Health Technology
|
| O: 14.07%
H: 0.65%
C: -6.49%
fda phase 1 cartilage trial phase 3 phase 2 clinical hold
First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna’s Next Generation COVID-19 Vaccine
Published: 2021-03-15 (Crawled : 15:00) - biospace.com/
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: -0.16%
H: 5.18%
C: 5.04%
covid phase 1 vaccine phase 3 phase 2 covid-19
aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications
Published: 2021-03-15 (Crawled : 15:00) - biospace.com/
LIFE | $1.595 -1.54% -1.57% 290K
|
Health Technology
|
| O: 4.41%
H: 1.42%
C: -5.39%
covid phase 2 positive respiratory trial biomarkers
Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b CONTROL Study in Congenital Ichthyosis
Published: 2021-03-15 (Crawled : 14:00) - biospace.com/
TMBR | $0.3426 -2.69% 3K
|
Health Technology
|
| O: 4.84%
H: 2.69%
C: -5.38%
phase 2 phase 2b enroll
Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis:
Published: 2021-03-15 (Crawled : 13:00) - biospace.com/
GLTO | $0.6501 -7.21% -7.77% 76K
|
Health Technology
|
| O: 1.69%
H: 1.98%
C: -7.19%
phase 2 fibrosis phase 2b
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
Published: 2021-03-15 (Crawled : 13:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 9.01%
H: 116.14%
C: 69.12%
solid tumors ongoing phase 1 trial phase 3 phase 2
Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
Published: 2021-03-15 (Crawled : 11:00) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: 1.51%
H: 3.54%
C: -6.45%
phase 2 dermatitis trial atopic dermatitis phase 2b enroll
UPDATE - Nouveau Monde Announces Phase 2 of What Is Planned to Become North America’s Largest Fully Integrated Anode Material Production Facility – Supported by Strong Economics and Carbon Neutrality
Published: 2021-03-13 (Crawled : 00:00) - globenewswire.com
XYF | News | $3.815 -1.74% 0.39% 5.4K
|
Finance
| Email alert
Add to watchlist
OLN | $53.07 -0.92% 0.0% 800K
|
Process Industries
| Email alert
Add to watchlist
phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.